# Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease

> **NCT06774040** · PHASE2 · NOT_YET_RECRUITING · sponsor: **VivaCell Biotechnology España** · enrollment: 30 (estimated)

## Conditions studied

- Peripheral Arterial Disease

## Interventions

- **DRUG:** Etribnabdione 25 mg BID
- **DRUG:** Etribnabdione 50 mg BID

## Key facts

- **NCT ID:** NCT06774040
- **Lead sponsor:** VivaCell Biotechnology España
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-03
- **Final completion:** 2027-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06774040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06774040, "Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06774040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*